Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2017-09-01Clinical Trial Update: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis [NA]
A clinical trial assessing the safety and effects of autologous adipose-derived stromal cells in patients with multiple sclerosis has been w…
-
CLINICAL_TRIALS withdrawal · 2017-04-25Clinical Trial Update: Improving Memory in Patients With Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating a memory-improvement intervention for patients with multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-21Clinical Trial Update: Safety and Efficacy of Fingolimod in MS Patients in China [Phase 3]
Clinical trial of fingolimod in relapsing-remitting multiple sclerosis in China was withdrawn during Phase 3.
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis [Phase 2]
A Phase 2 study evaluating 5 weeks of treatment with BGG492 for muscle spasticity in patients with multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon [Phase 4]
A Phase 4 trial evaluating fingolimod (Gilenya) in patients with neutralizing antibodies against interferon has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-12-29Clinical Trial Update: Alternative Treatment Paradigm for Natalizumab Trial [Phase 2]
A Phase 2 trial evaluating natalizumab for multiple sclerosis has been withdrawn. The sponsor indicates the study is no longer active.
-
CLINICAL_TRIALS withdrawal · 2016-09-26Clinical Trial Update: Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating the safety and brain-protective effects of Theaphenon 95% (EGCG) in multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-24Clinical Trial Update: A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis. [Phase 2]
A Phase 2 trial evaluating an A4I antagonist for relapsing multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-11Clinical Trial Update: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled study evaluating nabiximols as add-on therapy for spasticity in multiple sclerosis ha…
-
CLINICAL_TRIALS withdrawal · 2016-08-04Clinical Trial Update: A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating testosterone treatment for men with multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS [Phase 4]
A Phase 4 trial evaluating the mechanism of action of dimethyl fumarate in relapsing multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients [NA]
This clinical trial evaluating functional changes after percutaneous venoplasty in patients with Multiple Sclerosis and Chronic Cerebrospina…
-
CLINICAL_TRIALS withdrawal · 2015-09-07Clinical Trial Update: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate [Phase 4]
A Phase 4 clinical trial evaluating fatigue in people with relapsing-remitting multiple sclerosis treated with dimethyl fumarate has been wi…
-
CLINICAL_TRIALS withdrawal · 2015-03-10Clinical Trial Update: Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) [Phase 3]
A Phase 3 trial comparing double-dose Betaferon to the approved dose in early secondary progressive multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-10-09Clinical Trial Update: Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness [NA]
The clinical trial evaluating treadmill training for chronic multiple sclerosis, assessing efficacy and cost-effectiveness, has been withdra…
-
EMA withdrawal · 2014-09-01EMA Refused: Nerventra (laquinimod) — Teva Pharma GmbH
EMA refused Teva's Nerventra (laquinimod) application for multiple sclerosis, indicating a negative regulatory decision.
-
CLINICAL_TRIALS withdrawal · 2013-04-18Clinical Trial Update: Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA) [NA]
Clinical trial evaluating CPAP treatment for fatigue in patients with multiple sclerosis and obstructive sleep apnea has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-06-14Clinical Trial Update: Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. [Phase 2]
A Phase 2 trial investigating immunoregulation by controlled parasite exposure in multiple sclerosis has been withdrawn.
-
EMA withdrawal · 2011-02-23EMA Application withdrawn: Movectro (cladribine) — Merck Serono Europe Limited
EMA withdrew the application for Movectro (cladribine) by Merck Serono Europe Limited for multiple sclerosis.
-
CLINICAL_TRIALS withdrawal · 2010-09-30Clinical Trial Update: Visual Impairment, Oscillopsia and Multiple Sclerosis
A clinical trial investigating visual impairment and oscillopsia in Multiple Sclerosis was terminated.
-
CLINICAL_TRIALS withdrawal · 2010-06-03Clinical Trial Update: Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment [Phase 1]
A Phase 1 trial evaluating nasal dexamethasone for multiple sclerosis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2009-07-22Clinical Trial Update: Phase II High-Dose Cyclophosphamide for Multiple Sclerosis [Phase 2]
A Phase II trial evaluating high-dose cyclophosphamide for multiple sclerosis has been withdrawn.
-
EMA withdrawal · 2009-05-29EMA Application withdrawn: Biferonex (interferon beta-1a) — BioPartners GmbH
The EMA withdrew the application for Biferonex (interferon beta-1a) by BioPartners GmbH for multiple sclerosis.